GSK, CureVac Expand Licensing Agreement 0 03.07.2024 10:57 The Wall Street Journal Under a new licensing deal with CureVac, GSK will acquire full rights to develop, manufacture and commercialize internationally messenger RNA, or mRNA, candidate vaccines for influenza and Covid-19. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
